{"id":"73684cdeb4ef","type":"article","url":"https://hartvaat.nl/2026/09/07/nieuwe-aha-acc-hypertensierichtlijn-2025-risicogebaseerd-behandeladvies-prevent-/","title":"Nieuwe AHA/ACC-hypertensierichtlijn 2025: risicogebaseerd behandeladvies, PREVENT-formule en renale denervatie","title_en":"The 2025 AHA/ACC Hypertension Guidelines: Key Updates, Historical Context, and Clinical Implications.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Current cardiology reports","doi":"10.1007/s11886-026-02413-0","source_url":"https://doi.org/10.1007/s11886-026-02413-0","authors":["John M Giacona","Wanpen Vongpatanasin"],"significance":8,"published":"2026-09-15","source_date":"2026-09-07","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"The 2025 AHA/ACC hypertension guideline maintains the <130/80 mmHg treatment goal but adopts a strictly risk-based approach, recommending pharmacotherapy for stage-1 hypertension once the 10-year ASCVD risk reaches 7.5%. Key updates include the race-free PREVENT risk calculator, broader primary aldosteronism screening, routine urine albumin-to-creatinine ratio testing, and cautious incorporation of renal denervation. Clinically, the focus shifts toward precise blood pressure measurement, timely treatment intensification, and widespread use of single-pill combinations for stage-2 hypertension.","created":"2026-09-08T01:15:45Z","updated":"2026-09-08T01:15:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De 2025-richtlijn van de AHA/ACC voor hypertensie behoudt de streefwaarde <130/80 mmHg, maar verschuift naar een strikt risicogebaseerd behandeladvies met een drempel van 7,5% 10-jarig cardiovasculair risico voor fase-1 hypertensie. Belangrijkste updates zijn de introductie van de race-vrije PREVENT-berekening, bredere screening op primair aldosteronisme, routine-urinealbuminurie, en voorzichtige integratie van renale denervatie. Voor de klinische praktijk betekent dit een nadruk op nauwkeurige bloeddrukmeting, snelle therapie-intensificatie en het gebruik van single-pill combinaties bij fase-2 hypertensie.","abstract_original":"PURPOSE OF REVIEW: This review examines the 2025 American Heart Association/American College of Cardiology multisociety hypertension guideline, placing its recommendations in historical context and evaluating the supporting evidence across major clinical populations. RECENT FINDINGS: The 2025 guideline retains the 2017 blood pressure categories and treatment goal of less than 130/80 mmHg but introduces the race-free PREVENT equations, uses a 7.5% 10-year risk threshold to guide pharmacologic treatment of stage-1 hypertension, and encourages systolic blood pressure below 120 mmHg in selected high-risk patients. Additional updates include single-pill combination therapy for stage-2 hypertension, broader primary aldosteronism screening, routine urine albumin-to-creatinine ratio measurement, removal of race-based drug selection, and cautious incorporation of renal denervation. Recent trials strengthen the evidence for intensive lowering, including in diabetes and older adults. The 2025 guideline advances a risk-based, measurement-dependent approach. The principal challenge is no longer identifying effective treatments but delivering accurate measurement, timely intensification, and sustained follow-up at scale."}